TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05419492: A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome

Sponsor: Encoded Therapeutics · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 113 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$1,552,100

Rescue Site Savings

+$1,015,920

Unlock Full NCT05419492 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05419492 Rescue Dossier →